|Day Low/High||237.50 / 240.80|
|52 Wk Low/High||195.50 / 322.68|
The company has spent $600 million weighing a potential breakup.
With the Fed decision behind it, the market focuses on earnings and oil. In the portfolio, we added to three positions and exited from one.
Hedge fund billionaire Dan Loeb owns a greater than 17% stake in the newly public developer of a drugs including those for treatment of psoriasis.
Cramer's a big fan of Flex' technology and says Walt Disney may look like a dog now but it will soon have its day.
Some companies have powerful trends to bolster their numbers, Fed or no Fed, Cramer says.
The Irish drugmaker isn't likely done making deals, even though it just made two, and it could take a look at Alder Biopharmaceuticals next, analysts believe.
Stocks add to gains on Wednesday afternoon after the Federal Reserve opts to leaves rates unchanged at its September meeting.
Stocks hold higher on Wednesday as investors await a policy decision from the Federal Reserve.
Stock futures climb after the Bank of Japan makes moves to tackle deflation, while U.S. investors await a policy decision from their own central bank.
Gains from one day are being wiped out the next and vice versa, Cramer says.
Allergan (AGN) announced today that it would acquire Akarna Therapeutics for $50 million, marking its second acquisition of a company that specializes in fatty liver disease treatment.
- Acquisition Adds Global Rights to AKN-083, a Potentially Best-in-Class Preclinical FXR Agonist for the Treatment of NASH -
Wall Street makes few big moves on Tuesday as investors opt to sit on the sidelines ahead of a major day of monetary policy news.
Stocks rally and then get smacked down in this inconsistent atmosphere.
Stocks move slightly higher Tuesday as nerves peak over how the Federal Reserve and the Bank of Japan will vote in their separate two-day meetings.
Allergen (AGN) said it would acquire Tobira Therapeutics (TBRA) for up to $1.7 billion on Tuesday.
Jim Cramer believes Allergan paid too much for Tobira unless CEO Brent Saunders can prove that he knows something about the company that other market participants do not.
Indicators driven by price and volume are not calling out for immediate purchase.
Stocks are higher Tuesday as Federal Open Market Committee members convene for their widely anticipated meeting.
Allergan (AGN) agreed to acquire Tobira Therapeutics (TBRA) for up to $1.695 billion on Tuesday.
What to do with $40 billion? That is the question facing Allergan (AGN). One biotechnology stock which stands out as a potential target for Allergan is Applied Genetic Technologies (AGTC).
Stock futures move higher on Tuesday as Federal Open Market Committee members convene for their widely anticipated meeting.
- Acquisition Adds Global Rights to Highly Differentiated Compounds to Treat Multi-Factorial Elements of NASH -
Doug Kass shares his thoughts on Wells Fargo and Warren Buffett.
The market gets pushed and pulled by the Fed, oil and loads of economic reports. Meanwhile, the portfolio includes a new name.